Swedish cancer diagnostics company INIFY Laboratories AB (Euronext Growth Oslo:INIFY) announced on Wednesday that it is expanding its operations into the United Kingdom.
The company plans to invest approximately SEK150m to establish a new laboratory in the UK, aiming to address challenges in prostate cancer care.
The UK market for cancer diagnostics is estimated to be significantly larger than Sweden's, with around 120,000 patients annually requiring prostate cancer diagnosis. Inify believes its technology can improve response times and quality of care in the UK healthcare system.
Initial samples from the UK will be handled by Inify's Swedish laboratory during the establishment phase. The company expects the new UK laboratory to be operational in early 2026.
In addition to prostate cancer, Inify plans to offer diagnostics for gastrointestinal diseases, a market with a significantly larger volume of samples and a wider range of conditions.
(EUR1=SEK11.42)
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD